OralVueAI

OralVue AI - Machine Learning for Early Oral Pathology Detection

Oral cancer and its precursor lesions are among the most time-sensitive diagnoses in dentistry. When caught early, outcomes are often excellent; when caught late, they are frequently not. Yet the earliest stages of these lesions are easy to miss in a routine dental visit — the signs can be subtle, visually ambiguous, and scattered across the oral cavity in places a clinician may have only seconds to examine.

OralVue AI is a clinical decision-support platform Dr. Adatrow co-founded in January 2023 to change that math. Built at the intersection of dentistry, oral pathology, and machine learning, the application assists clinicians in identifying suspicious oral soft-tissue lesions – including potentially malignant conditions – earlier in the diagnostic window, when intervention is most effective.

The work reflects a conviction that has shaped Dr. Adatrow’s career: that the best applications of new technology in dentistry are the ones that extend clinical judgment rather than replace it. OralVue AI is designed to give every practitioner – from a solo general dentist to a specialty clinic – a second set of eyes trained on thousands of pathology cases, making early detection more consistent across the profession and, ultimately, improving patient outcomes.

  • Founded - January 2023
  • Role - Co-Founder; clinical insight, strategic direction, product development vision
  • Domain - Dentistry · Oral Pathology · Machine Learning
  • Focus - Early detection of oral soft-tissue lesions, including potentially malignant conditions
  • Clinical Significance - Delayed diagnosis of oral lesions is associated with significant morbidity and reduced survival; early detection meaningfully changes outcomes

OralVueAI

Overview & Background

In January 2023, Dr. Adatrow co-founded OralVueAI — an artificial-intelligence-powered oral health application focused on the detection of oral pathology lesions, including potentially malignant conditions. The platform sits at the intersection of dentistry, oral pathology, and machine learning.

Leveraging his clinical background in oral medicine, periodontology, and implant surgery, Dr. Adatrow contributed clinical insight, strategic direction, and product development vision to the venture. OralVueAI represents one of a small number of AI-native applications designed specifically for the identification of oral soft-tissue lesions — a domain where delayed diagnosis is associated with significant morbidity.

In June 2025, Dr. Adatrow also joined the board of Co Axis International, a data center company, broadening his engagement with the technology sector.

Platform Details

Application & Scope

Application Type

AI-Powered Oral Health Application

OralVueAI is an artificial-intelligence-powered application — AI-native by design, not retrofitted onto existing software. The platform applies machine learning to oral soft-tissue imaging for the purpose of lesion identification and flagging.
Clinical Domain

Oral Pathology Detection

The application is focused specifically on oral soft-tissue lesions — a domain distinct from radiographic dental AI tools. Potentially malignant conditions including oral squamous cell carcinoma are among the target detection categories.
Market Position

Among the First AI-Native Oral Pathology Platforms

OralVueAI represents one of a small number of AI-native applications designed specifically for identification of oral soft-tissue lesions - as distinct from broader dental AI tools focused on radiographic caries detection or periodontal bone level measurement.

Clinical Background

Research Foundation in Oral Cancer Pharmacology

Dr. Adatrow's research at Indiana University (2004–2006) examined DMAPT anti-cancer activity in oral squamous cell carcinoma cell lines — providing scientific grounding in oral malignancy biology that informs his clinical input to OralVueAI.
Clinical Significance

Oral Pathology & Delayed Diagnosis

Oral soft-tissue lesions — including those with malignant potential — are visually accessible but frequently missed or inadequately assessed during routine dental examinations. Delayed diagnosis is associated with significantly worse outcomes and increased morbidity. OralVueAI was developed to address this gap through AI-augmented lesion identification, extending the diagnostic reach of the platform to practitioners who may not have specialist-level oral pathology training.

Dr. Adatrow's Role

Contribution as Co-Founder

Dr. Adatrow’s role at OralVueAI is that of a co-founder who contributed clinical expertise and strategic direction to the venture from its founding in January 2023. His background spans oral medicine, periodontology, implant surgery, and original research in oral cancer pharmacology — providing a clinical foundation for the platform’s development.

His 20+ years of clinical practice diagnosing and managing oral lesions, combined with his academic research in oral squamous cell carcinoma pharmacology (Indiana University, 2004–2006), informed the clinical logic underlying the platform’s approach to lesion identification.

Clinical Insight

20+ years of oral medicine and periodontology clinical experience informing lesion classification and platform clinical logic

Strategic Direction

Shaping the platform's development priorities, clinical scope, and positioning within the dental AI landscape

Product Development Vision

Defining clinical utility requirements, workflow integration considerations, and practitioner-facing output specifications

Research Foundation

Oral cancer pharmacology research at Indiana University (2004–2006) — DMAPT activity in oral squamous cell carcinoma — providing scientific grounding in oral malignancy biology

Additional Technology Role

Co Axis International - Board Member

In June 2025, Dr. Adatrow joined the board of Co Axis International, a data center company. This board appointment reflects his expanded engagement with the technology sector following the founding of OralVueAI in 2023.

Coaxis
June 2025 — Present